A study by Stanford Medicine researchers in older mice may lead to treatments that help seniors regain muscle strength lost to aging. Muscle stem cells—which are activated in response to muscle injury to regenerate damaged muscle tissue—lose their potency with age. A study from the National Health and Nutrition Examination Survey showed that five percent … Continue reading Study could pave the way in reducing decline in muscle strength as people age
CD47
Saying thanks and farewell to a friend
Tom Howing In this job you get to meet a lot of remarkable people, none more so than the patients who volunteer to take part in what are giant experiments. They are courageous pioneers, willing to be among the first people to ever try a new therapy, knowing that it may not help them and, … Continue reading Saying thanks and farewell to a friend
A model for success
Dr. Maria Millan, CIRM's President & CEO Funding models are rarely talked about in excited tones. It’s normally relegated to the dry tomes of academia. But in CIRM’s case, the funding model we have created is not just fundamental to our success in advancing regenerative medicine in California, it’s also proving to be a model … Continue reading A model for success
CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Mark Chao, M.D., Ph.D., cofounder of Forty Seven, Inc. and current VP of oncology clinical research at Gilead Sciences An antibody therapeutic, magrolimab, being tested for myelodysplastic syndrome (MDS), a group of cancers in which the bone marrow does not produce enough healthy blood cells , was granted breakthrough therapy designation with the Food and Drug Administration … Continue reading CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
CIRM Highlights Industrial Alliance Program (IAP)
In the addition to the innovative scientists and clinicians who conceive and develop novel experimental therapies, it takes a village to drive a promising experimental therapy through phases of clinical trials, regulatory marketing approval, and commercialization before it becomes broadly accessible to patients with unmet medical needs. In this case, the village is the broader … Continue reading CIRM Highlights Industrial Alliance Program (IAP)
Big time validation for early support
It’s not every day that a company and a concept that you helped support from the very beginning gets snapped up for $4.9 billion. But that’s what is happening with Forty Seven Inc. and their anti-cancer therapies. Gilead, another California company by the way, has announced it is buying Forty Seven Inc. for almost $5 … Continue reading Big time validation for early support
Two CIRM supported studies highlighted in Nature as promising approaches for blood disorders
Blood stem cells (blue) are cleared from the bone marrow (purple) before new stem cells can be transplanted.Credit: Dennis Kunkel Microscopy/SPL Problems with blood stem cells, a type of stem cell in your bone marrow that gives rise to various kinds of blood cells, can sometimes result in blood cancer as well as genetic and … Continue reading Two CIRM supported studies highlighted in Nature as promising approaches for blood disorders
Newly discovered “don’t eat me” signal shows potential for ovarian and triple-negative breast cancer treatment
Stanford researchers have found that cancer cells have a protein called CD24 on their surface that enables them to protect themselves against the body's immune cells. Courtesy of Shutterstock Getting a breast cancer diagnosis is devastating news in and of itself. Currently, there are treatment options that target three different types of receptors, which are … Continue reading Newly discovered “don’t eat me” signal shows potential for ovarian and triple-negative breast cancer treatment
CIRM funded clinical trial shows promising results for patients with blood cancers
An illustration of a macrophage, a vital part of the immune system, engulfing and destroying a cancer cell. Antibody 5F9 blocks a "don't eat me" signal emitted from cancer cells. Courtesy of Forty Seven, Inc. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both types of blood cancers that can be difficult to treat. CIRM … Continue reading CIRM funded clinical trial shows promising results for patients with blood cancers
Saying goodbye to a good friend and a stem cell pioneer: Karl Trede
Sometimes even courage and determination are not enough. Karl Trede had courage and determination in droves as he fought a 12 year battle against cancer. He recently lost that battle. But he remains an inspiration for all who knew him. I got to know Karl for our 2016 Annual Report. Karl had been diagnosed with … Continue reading Saying goodbye to a good friend and a stem cell pioneer: Karl Trede
The Stem Cellar 